Advances and Challenges in Trials of Local Therapy for Patients With Oligometastatic or Oligoprogressive Disease

Article Oncology

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer

Xiao-Shan Wang et al.

Summary: Adding upfront local therapy using RT significantly improves PFS and OS for EGFR-mutated NSCLC compared to the use of a first-line TKI alone.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2023)

添加到收藏夹

Article Oncology

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium

Stephanie G C Kroeze et al.

LANCET ONCOLOGY (2023)

添加到收藏夹

Editorial Material Medicine, General & Internal

Why Diverse Clinical Trial Participation Matters

Aaron L. Schwartz et al.

Summary: Efforts to increase diversity in clinical trials should prioritize improving the trustworthiness and fairness of U.S. health care, rather than solely focusing on knowledge generation.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer The EXTEND Phase 2 Randomized Clinical Trial

Chad Tang et al.

Summary: This randomized clinical trial investigated the addition of metastasis-directed therapy (MDT) to hormone therapy in men with oligometastatic prostate cancer. The study found that combining MDT with intermittent hormone therapy significantly improved progression-free survival and eugonadal progression-free survival, providing a new treatment strategy for prostate cancer patients.

JAMA ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

The oligometastatic paradigm and the role of radiotherapy

Killian Nugent et al.

Summary: Most cancer-related deaths are caused by metastatic disease. Evidence suggests that a subgroup of metastatic patients can benefit from local resection or ablation of their metastatic sites. These patients are in an oligometastatic state, where locally ablative therapy prolongs survival and sometimes achieves cure. It is a challenge for oncologists to select the appropriate patients and integrate ablative technologies with systemic treatments.

CLINICAL MEDICINE (2023)

添加到收藏夹

Article Urology & Nephrology

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial

Shankar Siva et al.

Summary: The RAPPORT trial investigated the combination of high-dose precision radiotherapy and a short course of immunotherapy in patients with low-volume metastatic kidney cancer. The results showed that this treatment regimen was well tolerated, with excellent cancer control in known disease sites, and a proportion of patients were free from cancer relapse in the longer term. These findings are encouraging and warrant further investigation.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Oncology

Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy

Hanbo Chen et al.

Summary: A prognostic model for overall survival in patients with extracranial oligometastatic disease treated with stereotactic body radiation therapy (SBRT) has been developed and validated.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Oncology

A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

L. Nicosia et al.

Summary: This study investigated the efficacy and predictive factors of SABR in the treatment of lung colorectal metastases using a large multicenter retrospective database. The results showed that SABR could delay the progression to polymetastatic disease (PMD) and provide a relatively long disease-free period in selected cases. Furthermore, predictive factors were identified for treatment personalization.

RADIOTHERAPY AND ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives

Remy Kinj et al.

Summary: Stereotactic radiation therapy (SBRT) is a type of highly precise radiation therapy that delivers a small number of high doses of radiation to a target area. It plays a crucial role in the treatment of early primary cancer and oligometastatic disease, aiming to achieve complete remission. SBRT is commonly used for various disease types, and numerous randomized clinical trials have demonstrated its efficacy and safety. This article provides a review of the technical and clinical aspects of SBRT based on disease type and clinical indication.

CANCERS (2022)

添加到收藏夹

Review Oncology

Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations

Antonio Rossi et al.

Summary: Oligoprogression refers to the limited number and/or sites of metastases in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), characterized by a slower tumor biology. The optimal approach to diagnosing and managing this disease state is still unclear, and further research is needed to address gaps in patient selection, progression type, resistance mechanisms, optimal systemic therapy, and the tumor microenvironment.

CANCERS (2022)

添加到收藏夹

Article Oncology

Progression-free survival: it is time for a new name

Bishal Gyawali et al.

LANCET ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Final Analysis of Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression Trial - A Randomized Study of Stereotactic Body Radiotherapy for Oligoprogressive Metastatic Lung and Breast Cancers

C.J. Tsai et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Oncology

Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.

Rachel Woodford et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557).

Steven J. Chmura et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial

Robert Olson et al.

Summary: This study confirms that the incidence of high-grade toxic effects in the large cohort of patients receiving SABR for oligometastases is less than 5%. The lower rates of toxic effects compared to previous studies may support further enrollment in randomized phase 3 clinical trials.

JAMA ONCOLOGY (2022)

添加到收藏夹

Review Medicine, General & Internal

Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy A Systematic Review

Alexander Fabian et al.

Summary: This systematic review examined the use and reporting of patient-reported outcomes (PROs) in clinical trials of palliative radiotherapy. Among the 225 eligible trials, 20% used a PRO as a primary endpoint and 31% used a PRO as a secondary endpoint. The most common PRO measures were the Numeric Rating Scale/Visual Analogue Scale, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30, and trial-specific unvalidated measures. Adherence to CONSORT-PRO reporting guidelines was generally poor or moderate. The study suggests the need for improved use and reporting of PROs in future trials, particularly as primary endpoints.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Review Health Care Sciences & Services

Electronic patient-reported outcomes (e-PROMs) in palliative cancer care: a scoping review

Letteria Consolo et al.

Summary: This scoping review explores the technological innovation of electronic patient-reported outcome measures (e-PROMs) in cancer palliative care and how the collected data can impact symptom monitoring and management, as well as facilitate improved communication between healthcare professionals and patients.

JOURNAL OF PATIENT-REPORTED OUTCOMES (2022)

添加到收藏夹

Review Oncology

A critical review on oligometastatic disease: a radiation oncologist's perspective

Pietro Pacifico et al.

Summary: This review summarizes the critical features of OligoMetastatic Disease (OMD) and provides a set of practical questions to guide radiation oncologists in patient selection and treatment choices.

MEDICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort

Bart J. Pielkenrood et al.

Summary: In patients with painful bone metastases, stereotactic body radiation therapy (SBRT) did not significantly improve pain response. Some patients preferred conventional external beam radiation therapy over SBRT, and about one in five patients starting SBRT treatment was unable to complete it.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

添加到收藏夹

Article Health Policy & Services

Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment

Andrew G. Robinson et al.

Summary: Most metastatic cancer patients undergoing palliative chemotherapy consider delayed imaging progression in the absence of survival benefit to be of low value. Therefore, PFS should not be assumed to have intrinsic value to patients when making drug treatment and policy decisions without established surrogacy for overall survival or quality of life.

JOURNAL OF CANCER POLICY (2021)

添加到收藏夹

Article Oncology

Imaging and its Impact on Defining the Oligometastatic State

Ali Pirasteh et al.

Summary: Successful treatment of oligometastatic disease relies on timely detection and localization, with imaging playing a crucial role. Challenges in managing OMD are reflected in imaging, despite technological advances. This review highlights the role of imaging in detecting and evaluating OMD in various organ systems, aiming to provide practical guidance for clinicians.

SEMINARS IN RADIATION ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis

Xuguang Chen et al.

Summary: Late metastatic presentation is associated with improved survival and delayed progression in patients with OMD treated with SBRT.

CANCER MEDICINE (2021)

添加到收藏夹

Article Oncology

Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.

Piet Ost et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation

Matthias Guckenberger et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Health Care Sciences & Services

International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer

Morten Aa Petersen et al.

QUALITY OF LIFE RESEARCH (2020)

添加到收藏夹

Article Oncology

Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial

Robert Olson et al.

BMC CANCER (2020)

添加到收藏夹

Article Oncology

ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI

Oscar S. H. Chan et al.

LUNG CANCER (2020)

添加到收藏夹

Article Oncology

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer The ORIOLE Phase 2 Randomized Clinical Trial

Ryan Phillips et al.

JAMA ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Yolande Lievens et al.

RADIOTHERAPY AND ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Prognostic and Predictive Biomarkers in Oligometastatic Disease

Kevin J. Barnum et al.

CANCER JOURNAL (2020)

添加到收藏夹

Article Oncology

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study

Daniel R. Gomez et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

David A. Palma et al.

LANCET (2019)

添加到收藏夹

Article Oncology

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial

Joshua M. Bauml et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial

David A. Palma et al.

BMC CANCER (2019)

添加到收藏夹

Article Oncology

Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report

Anne-Marie C. Dingemans et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Predictive Factors for Response and Survival in a Cohort of Oligometastatic Patients Treated With Stereotactic Body Radiation Therapy

Davide Franceschini et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

添加到收藏夹

Article Oncology

Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy

Ciro Franzese et al.

RADIOTHERAPY AND ONCOLOGY (2019)

添加到收藏夹

Review Oncology

Combining stereotactic body radiation therapy with immunotherapy: current data and future directions

Alexander J. Lin et al.

TRANSLATIONAL LUNG CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial

Puneeth Iyengar et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement

Karen M. Winkfield et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937

Elizabeth M. Gore et al.

JOURNAL OF THORACIC ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Identifying barriers to accrual in radiation oncology randomized trials

J. M. Laba et al.

CURRENT ONCOLOGY (2017)

添加到收藏夹

Article Health Care Sciences & Services

Cohort Multiple Randomised Controlled Trials (cmRCT) design: efficient but biased? A simulation study to evaluate the feasibility of the Cluster cmRCT design

Alexander Pate et al.

BMC MEDICAL RESEARCH METHODOLOGY (2016)

添加到收藏夹

Article Oncology

Decision Aids Can Support Cancer Clinical Trials Decisions: Results of a Randomized Trial

Mary C. Politi et al.

ONCOLOGIST (2016)

添加到收藏夹

Review Medicine, General & Internal

The Strength of Association Between Surrogate End Points and Survival in Oncology A Systematic Review of Trial-Level Meta-analyses

Vinay Prasad et al.

JAMA INTERNAL MEDICINE (2015)

添加到收藏夹

Review Health Care Sciences & Services

Implementing patient-reported outcome measures in palliative care clinical practice: A systematic review of facilitators and barriers

Barbara Antunes et al.

PALLIATIVE MEDICINE (2014)

添加到收藏夹

Article Oncology

Oligometastases revisited

Ralph R. Weichselbaum et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2011)

添加到收藏夹

Article Medicine, General & Internal

Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes

Linda E. Levesque et al.

BRITISH MEDICAL JOURNAL (2010)

添加到收藏夹

Editorial Material Oncology

Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

James R. Anderson et al.

JOURNAL OF CLINICAL ONCOLOGY (2008)

添加到收藏夹

Advances and Challenges in Trials of Local Therapy for Patients With Oligometastatic or Oligoprogressive Disease

相关参考文献

导出引文

分享论文